Pine Brook, NJ (PRWEB) December 11, 2012
BizTech Magazines’ Winter 2013 edition has featured Diopsys’ cutting-edge software and specially integrated hardware that powers the Enfant® Pediatric VEP Vision Testing System. The new Hardware & Software Case Study, A New Outlook on Vision Testing in Early Childhood, includes an interview with Diopsys COO, Don Lepone. The story also describes the important case study of Nora Turner, a then six month old baby girl, who was discovered to have bilateral retinoblastoma, eye cancer, after she failed an Enfant® VEP eye test.
The Enfant® is an easy-to-operate, child-friendly, non-invasive device used to test for visual deficits in children six months of age and older. The Enfant® is the only objective vision testing device for the pediatrician available today that is capable of evaluating the entire visual pathway to detect visual deficits such as optic nerve disorders, severe refractive errors, and other problems that could lead to amblyopia. The device uses advanced Visual Evoked Potential (VEP) technology to measure the strength and speed of the vision system.
BizTech Magazine quotes Don as saying, “Evoked potentials are used all over the world for lots of different things. We’ve refined the technology so that the device can be used in an office setting.” Roughly 600 pediatric practices are currently using this high tech device to test their patients’ vision.
Diopsys, Inc. (http://www.diopsys.com/) is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care solutions. The company specializes in the development and marketing of patient-friendly, non-invasive vision testing devices utilizing electrophysiological technology.
Diopsys has developed and markets the patented Diopsys® NOVA-VEP Vision Testing Systems utilized by optometrists and ophthalmologists to help in the detection, diagnosis and treatment of vision disorders, including glaucoma. Diopsys also provides the Enfant® Pediatric VEP Vision Testing System, a device used in testing for visual deficits, including amblyopia, in children as young as six months of age.